Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abrocitinib - Pfizer

Drug Profile

Abrocitinib - Pfizer

Alternative Names: JAK 1 inhibitor; PF 04965842; PF-4965842

Latest Information Update: 17 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antipsoriatics; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Discontinued Lupus vulgaris; Plaque psoriasis

Most Recent Events

  • 14 Dec 2019 Pfizer completes a phase I trial in Atopic dermititis (Healthy volunteers) in USA (PO, Tablet) (NCT04065633)
  • 09 Dec 2019 Pfizer completes a phase I pharmacokinetic trial (In volunteers) in China (PO, Tablet) (NCT04099563)
  • 05 Nov 2019 Pfizer completes a phase I trial (In volunteers) in USA and Belgium (PO) (NCT03660241)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top